Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707252 · ClinicalTrials.gov registry record · Phase 1
Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer
A Phase 1 study, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00707252: Clinical Trial Phase 1 study, sponsored by Louisiana State University Health Sciences Center Shreveport.
NCT00707252 is a Phase 1 study that was terminated before completion, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00707252, a Phase 1 study, was terminated before completion, sponsored by Louisiana State University Health Sciences Center Shreveport.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to study if the addition of the green tea extract, Polyphenon E, to Erlotinib is safe and if it has potential to improve outcomes in second line therapy for Advanced Stage IIIb/IV Non-small cell lung cancer.
Primary Outcome
Toxicity evaluation of all adverse events monitored by physical exam, weight, vital signs, Complete Blood Count (CBC), Complete Metabolic Panel (CMP), coagulation panel and Computed Tomography (CT) scans of the chest, abdomen and pelvis, CT/Magnetic Resonance Imaging (MRI) of the head.
Interventions
- DRUG Tarceva
- DRUG Polyphenon E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Why NCT00707252 stopped before completion
NCT00707252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Tarceva is the first listed.
NCT00707252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00707252 about?
NCT00707252 is a clinical study titled "Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer". The purpose of this study is to study if the addition of the green tea extract, Polyphenon E, to Erlotinib is safe and if it has potential to improve outcomes in second line therapy for Advanced Stage IIIb/IV Non-small cell lung cancer.
What is the current status of trial NCT00707252?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2008-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00707252?
The interventions under investigation include: Tarceva (DRUG), Polyphenon E (DRUG).
Who is sponsoring clinical trial NCT00707252?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00707252's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia